📋 Tender Overview
Project ID: 55995
Status: Approved
Location: Regional
Business Sector: Manufacturing and Services
Notice Type: Private
Environmental Category: B
Approval Date: 22 Jul 2025
Disclosure date: 14 Aug 2025
As permitted by paragraph 2.6 of Section III of the Access to Information Policy, disclosure of this PSD was deferred in accordance with paragraph 1.4.4 of the Directive on Access to Information.
As per section 1.4.2 (iii) of the Directive on Access to Information: "For Projects approved by Bank management where the Board of Directors has delegated the approval authority, the PSD shall be disclosed at the start of the relevant no-objection notification period to a member country of the Bank in accordance with Article 13 (iii) of the Agreement Establishing the EBRD."
Project Description
The senior secured loan in the amount of up to €23 million for the construction works within an existing, leased production facility, as well as equipment and commencing the plant operations. The facility will be located in Zilina region, Slovakia, and used for the production of the semaglutide-based diabetes type II medicine.
Transition Impact
ETI score: 68
- Integrated: The Project entails the first cross-border expansion of the local pharmaceutical manufacturer from Poland to Slovakia via greenfield production facility
- Inclusive: The Group will introduce new training programmes to equip employees (in Poland and Slovakia) with business-critical skills for advanced pharmaceutical manufacturing and research. This initiative responds to a shortage of qualified talent in the region.
Client Information
CELON PHARMA SLOVAKIA SRO
Celon Pharma Slovakia s. r. o. (the "Company") - established in October 2024 for the purpose of production of a semaglutide-based drug used primarily for the treatment of diabetes type II and secondarily in weight loss.
Celon Pharma S.A. (the "Group") is a Polish pharmaceutical company operating in the field of generic drugs manufacturing as well as R&D in the area of complex generic/biological drugs. The Group has its own production facility in central Poland together with an R&D centre.
